Fang Lue Pharmaceutical Company

Fanglue Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the development of innovative oncology therapies. The company employs a "license-in and self-development" model to advance a pipeline of precision medicines targeting significant unmet needs in the Chinese market. Its lead asset, FL-001, is a PARP inhibitor currently in Phase 3 clinical trials for the maintenance treatment of ovarian cancer. Fanglue's portfolio also includes inhibitors targeting Hsp90 and multi-kinase pathways, supported by a leadership team with deep expertise in global pharmaceutical R&D. The company aims to bridge the gap between international drug discovery and the rapidly growing Chinese healthcare sector.